Cancer News and Research

Latest Cancer News and Research

HBO treatments may improve neurological outcome after traumatic brain injury

Hard to Treat Diseases, Inc. (HTDS:PK), http://www.htdsmedical.com announced that researchers in its Slavica BioChem division have reported new positive results of experiments in which the potential beneficial effects of Hyperbaric oxygenation (HBO) after traumatic brain injury have been explored.

22 Oct 2009

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.

22 Oct 2009

New research suggests physical therapy helps restore variety of functions after neurological injury

New research suggests a tailored approach to physical therapy after a neurological injury such as a stroke, traumatic brain injury or spinal cord injury could help restore a wider variety of functions.

22 Oct 2009

Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab

Peregrine Pharmaceuticals, Inc. today reported positive results from its Phase II trial evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer.

22 Oct 2009

New health initiative focuses on environmentally-associated cancers

The Barbara Ann Karmanos Cancer Institute, in cooperation with Blue Cross Blue Shield of Michigan (BCBSM), will launch a targeted health initiative in January 2010 focused on environmentally-associated cancers.

22 Oct 2009

CHOP implements InforSense-based Translational Research Solution to study complex genetic disease

IDBS, the leading worldwide provider of research data management and analytics solutions to R&D organizations, today announced that The Children's Hospital of Philadelphia (CHOP), one of the leading pediatric hospitals and research facilities in the world, has implemented the InforSense-based Translational Research Solution to advance the understanding of complex genetic disease.

22 Oct 2009

Halozyme Therapeutics commences patient dosing in Phase 3 Enhanze trial with Herceptin

Halozyme Therapeutics, Inc. and Roche today announced dosing of the first patient in a Phase 3 registration trial using Enhanze™ technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation with Roche’s anticancer biologic, Herceptin (trastuzumab).

22 Oct 2009

OSI Pharmaceuticals reports total revenues of $111 million for the third quarter of 2009

OSI Pharmaceuticals, Inc. announced today its financial results for the Company’s third quarter ended September 30, 2009. The Company reported total revenues from continuing operations of $111 million for the third quarter of 2009 compared to revenues of $95 million for the third quarter of 2008, an 18% increase over the prior year period.

22 Oct 2009

TomoTherapy adds the TomoHD treatment system to its suite of advanced radiation therapy solutions

TomoTherapy Incorporated today announced that it has extended its suite of advanced radiation therapy solutions with the addition of the TomoHD™ treatment system, an efficient, all-purpose new system designed to make it easier for any radiation oncology department to adopt TomoTherapy® technology for its patient population.

22 Oct 2009

Breast cancer brought to the forefront of public discussion in the Middle East

Egypt and its historic Mediterranean seaport, Alexandria, will host the beginning of an extraordinary week of international events designed to bring breast cancer to the forefront of public discussion in the Middle East.

22 Oct 2009

Sexual dysfunction in cancer survivors rarely addressed by internists

Few internists who care for cancer survivors address issues of sexual dysfunction with their patients, according to a study led by Massachusetts General Hospital (MGH) researchers. In their article appearing in a November 2009 cancer survivor supplement to the Journal of General Internal Medicine, now available online, the investigators report that more than half the internists responding to a survey indicated they rarely or never discussed sexual problems with their patients who had survived cancer.

22 Oct 2009

GE and Eli Lilly develop tissue-based biomarker technology for cancer therapy

Scientists at GE Global Research, and researchers at Eli Lilly and Company today announced a significant advancement in cancer research resulting from the two companies’ collaboration formed in October 2007.

22 Oct 2009

GlaxoSmithKline's CERVARIX recommended by CDC for protection against cervical cancer

GlaxoSmithKline announced today that the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) recommended that CERVARIX® [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] be given to girls and young women to protect against cervical pre-cancers and cervical cancer caused by oncogenic HPV 16 and 18.

22 Oct 2009

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

Isis Pharmaceuticals, Inc. today announced positive top-line results from a Phase 2 study evaluating the safety and efficacy of ISIS 113715 in patients with type 2 diabetes. ISIS 113715 is a novel insulin sensitizer that reduces the expression of protein tyrosine phosphatase-1B (PTP-1B). The study showed consistent and statistically significant reductions in multiple short and intermediate measures of glucose control.

22 Oct 2009

Independent panel to rein in health costs gaining support

"As Congress grapples with how to rein in the high cost of healthcare in America, the option of outsourcing hard decisions to a new, independent commission is gaining momentum," the Christian Science Monitor reports.

22 Oct 2009

New partnership to create Translational Orthopedic Research Program

The creation of the Translational Orthopedic Research Program (TORP), a new partnership of Van Andel Research Institute (VARI) and its affiliate the Translational Genomics Research Institute (TGen), Spectrum Health, Orthopaedic Associates of Michigan (OAM), and the Michigan State University (MSU) College of Human Medicine, was announced today by officials of the sponsoring organizations who gathered at Van Andel Institute for the World Osteoporosis Day Summit, a meeting spotlighting local osteoporosis efforts.

22 Oct 2009

Crux Biomedical receives U.S. patent for its novel vena cava filter

Crux Biomedical Inc. announced today that it was awarded a U.S. patent, (US 7,582,100 B2), for its novel vena cava filter.

22 Oct 2009

Bioidentical Hormones for breast cancer prevention

For a sample of prevention awareness on Breast Cancer and overall health, there are key terms one is suggested to start on: BRCA; DHEA; Estradiol; Estriol; Free radicals; Insulin resistance; Melatonin; Premarin; Progesterone; SHBG; vitamin D.

22 Oct 2009

CWRU establishes collaborative research center to address common health issues in urban neighborhoods

Case Western Reserve University (CWRU) School of Medicine proudly announces the establishment of the CWRU Prevention Research Center for Healthy Neighborhoods (PRCHN), a collaborative research center to address common health issues faced in disadvantaged urban neighborhoods in and around Greater Cleveland.

22 Oct 2009

Certain molecules found to play an important role in regulating circadian rhythm: Study

Molecules that may hold the key to new ways to fight cancer and other diseases have been found to play an important role in regulating circadian rhythm, says Liheng Shi, a researcher in Texas A&M's Department of Veterinary Integrative Biosciences.

21 Oct 2009

Cancer News and Research

Latest Cancer News and Research

HBO treatments may improve neurological outcome after traumatic brain injury

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

New research suggests physical therapy helps restore variety of functions after neurological injury

Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab

New health initiative focuses on environmentally-associated cancers

CHOP implements InforSense-based Translational Research Solution to study complex genetic disease

Halozyme Therapeutics commences patient dosing in Phase 3 Enhanze trial with Herceptin

OSI Pharmaceuticals reports total revenues of $111 million for the third quarter of 2009

TomoTherapy adds the TomoHD treatment system to its suite of advanced radiation therapy solutions

Breast cancer brought to the forefront of public discussion in the Middle East

Sexual dysfunction in cancer survivors rarely addressed by internists

GE and Eli Lilly develop tissue-based biomarker technology for cancer therapy

GlaxoSmithKline's CERVARIX recommended by CDC for protection against cervical cancer

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

Independent panel to rein in health costs gaining support

New partnership to create Translational Orthopedic Research Program

Crux Biomedical receives U.S. patent for its novel vena cava filter

Bioidentical Hormones for breast cancer prevention

CWRU establishes collaborative research center to address common health issues in urban neighborhoods

Certain molecules found to play an important role in regulating circadian rhythm: Study

Understanding the DNA Damage Response in Innate Immunity eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in